On July 18th, Gelunhui reported that Changchun High-tech Industries (000661.SZ) announced that its holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as Jinsai Pharmaceutical), recently received a Notice of Acceptance issued by the National Medical Products Administration, with the product name of recombinant human follicle-CTP fusion protein injection.

Infertility is a problem affecting couples of childbearing age in various countries and regions around the world. With the decrease in the number of births in recent years and the acceleration of population aging, the state has promulgated multiple policies to encourage childbirth. The huge population base has resulted in a great demand for assisted reproductive technology. The recombinant human follicle-CTP fusion protein injection (FSH-CTP) developed by Jinsai Pharmaceutical is a biological product for therapeutic use classified as category 3.2 of registration and is intended to be used for women receiving assisted reproductive technology (ART) treatment to perform controlled ovarian stimulation (COS) to promote the development of multiple follicles.